Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

The Lancet

Volumn 390, Issue 10102, 2017, Pages 1603-1610

  Petousis Harris, Helen ^a   Paynter, Janine ^a   Morgan, Jane ^a,b   Saxton, Peter ^a   McArdle, Barbara ^a   Goodyear Smith, Felicity ^a   Black, Steven ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; MENINGOCOCCAL TYPE B CONJUGATE VACCINE; VACCINE;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHLAMYDIA; CHLAMYDIASIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; GONORRHEA; HUMAN; IMMUNIZATION; INCIDENCE; ISOLATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEISSERIA GONORRHOEAE; NEW ZEALAND; NUCLEIC ACID AMPLIFICATION; ODDS RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL HEALTH; YOUNG ADULT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHLAMYDIA INFECTIONS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GONORRHEA; HUMANS; MALE; MENINGOCOCCAL VACCINES; NEW ZEALAND; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 85021959305     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31449-6     Document Type: Article

References (39)

1. Newman, L, Rowley, J, Vander Hoorn, S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PloS One, 10, 2015, e0143304.
2. Tramont, EC, Gonococcal vaccines. Clin Microbiol Rev 2:suppl (1989), S74–S77.
3. Lewis, DA, Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis 27 (2014), 62–67.
4. Bolan, GA, Sparling, PF, Wasserheit, JN, The emerging threat of untreatable gonococcal infection. N Engl J Med 366 (2012), 485–487.
5. Kirkcaldy, RD, Harvey, A, Papp, JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance—the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 65 (2016), 1–19.
6. Edwards, JL, Jennings, MP, Apicella, MA, Seib, KL, Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit Rev Microbiol 2 (2016), 928–941.
7. Mehta, SD, Erbelding, EJ, Zenilman, JM, Rompalo, AM, Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection. Sex Transm Infect 79 (2003), 124–128.
8. Eyre, JH, Stewart, B, The treatment of gononcoccus infections by vaccines. Lancet 174 (1909), 76–81.
9. Greenberg, I, Diena, BB, Kenny, CP, Znamirowski, R, Preliminary studies on the development of a gonococcal vaccine. Bull World Health Organ 45 (1971), 531–535.
10. Greenberg, L, Diena, BB, Ashton, FA, et al. Gonococcal vaccine studies in Inuvik. Can J Public Health 65 (1974), 29–33.
11. Boslego, JW, Tramont, EC, Chung, RC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9 (1991), 154–162.
12. Zhu, W, Chen, C-J, Thomas, CE, Anderson, JE, Jerse, AE, Sparling, PF, Vaccines for gonorrhea: can we rise to the challenge?. Front Microbiol, 2, 2011, 124.
13. Jerse, AE, Bash, MC, Russell, MW, Vaccines against gonorrhea: Current status and future challenges. Vaccine 32 (2014), 1579–1587.
14. Pérez, O, del Campo, J, Cuello, M, et al. Mucosal approaches in Neisseria vaccinology. VacciMonitor 18 (2009), 53–55.
15. STI Surveillance Team. Sexually transmitted infections in New Zealand: annual surveillance report 2009, 2010, Institute of Environmental Science and Research, Wellington.
16. Whelan, J, Kløvstad, H, Haugen, I, Holle, M, Storsaeter, J, Ecologic study of meningococcal b vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis, 22, 2016, 1137.
17. Holst, J, Oster, P, Arnold, R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 9 (2013), 1241–1253.
18. Tinsley, CR, Nassif, X, Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: Two closely related bacteria expressing two different pathogenicities. Proc Natl Acad Sci USA, 93, 1996, 11 109–14.
19. Arnold, R, Galloway, Y, McNicholas, A, O'Hallahan, J, Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 29 (2011), 7100–7106.
20. Wind, CM, van der Loeff, MFS, Unemo, M, Schuurman, R, van Dam, AP, de Vries, HJ, Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae—a prospective cohort study. BMC Infect Dis, 16, 2016, 554.
21. Clarivet, B, Picot, E, Marchandin, H, et al. Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in asymptomatic patients under 30 years of age screened in a French sexually transmitted infections clinic. Eur J Dermatol 24 (2014), 611–616.
22. Institute of Environmental Science and Research. Sexually transmitted infections in New Zealand: annual surveillance report 2014, 2015, Institute of Environmental Science and Research, Porirua.
23. Fleiss, JL, Levin, B, Paik, MC, Statistical methods for rates and proportions, 2013, John Wiley & Sons, New York.
24. Weinberg, GA, Szilagyi, PG, Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201 (2010), 1607–1610.
25. CBG Health Research Limited. Evaluation of the meningococcal B immunisation national roll-out. Final report. http://www.health.govt.nz/publication/evaluation-meningococcal-b-immunisation-national-roll-out-final-report, November, 2006 (accessed June 28, 2017).
26. Barnett, JR, Coyle, P, Kearns, RA, Holes in the safety net? Assessing the effects of targeted benefits upon the health care utilization of poor New Zealanders. Health Soc Care Community 8 (2000), 159–171.
27. Manhart, LE, Aral, SO, Holmes, KK, et al. Influence of study population on the identification of risk factors for sexually transmitted diseases using a case-control design: the example of gonorrhea. Am J Epidemiol 160 (2004), 393–402.
28. Virji, M, Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat Rev Microbiol 7 (2009), 274–286.
29. Rosenqvist, E, Høiby, EA, Wedege, E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63 (1995), 4642–4652.
30. Davenport, V, Guthrie, T, Findlow, J, Borrow, R, Williams, NA, Heyderman, RS, Evidence for naturally acquired T cell mediated mucosal immunity to Neisseria meningitidis. J Immunol 171 (2003), 4263–4267.
31. Davenport, V, Groves, E, Horton, RE, et al. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis 198 (2008), 731–740.
32. Jackson, C, Lennon, D, Wong, S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Childhood 96 (2011), 744–751.
33. Bromhead, C, Miller, A, Jones, M, Whiley, D, Comparison of the cobas 4800 CT/NG test with culture for detecting Neisseria gonorrhoeae in genital and nongenital specimens in a low-prevalence population in New Zealand. J Clin Microbiol 51 (2013), 1505–1509.
34. Creighton, S, Tenant-Flowers, M, Taylor, CB, Miller, R, Low, N, Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean?. Int J STD AIDS 14 (2003), 109–113.
35. Vonck, RA, Darville, T, O'Connell, CM, Jerse, AE, Chlamydial infection increases gonococcal colonization in a novel murine coinfection model. Infect Immun 79 (2011), 1566–1577.
36. Hedges, SR, Sibley, DA, Mayo, MS, Hook, EW, Russell, MW, Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. J Infect Dis 178 (1998), 742–751.
37. Comanducci, M, Bambini, S, Brunelli, B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exper Med 195 (2002), 1445–1454.
38. Hadad, R, Jacobsson, S, Pizza, M, et al. Novel meningococcal 4CMenB vaccine antigens—prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS 120 (2012), 750–760.
39. Craig, AP, Gray, RT, Edwards, JL, et al. The potential impact of vaccination on the prevalence of gonorrhea. Vaccine 33 (2015), 4520–4525.